Ebracteolata compound B (ECB) is one major active component of both Euphorbia ebracteolata and Euphorbia fischeriana, which have been extensively used as a tuberculocide in the Asian countries. The aim of our present study was to characterize ECB metabolism in human liver microsomes, HepG2 cells, and recombinant human enzymes. One monohydroxylation metabolite, determined by mass spectrometry to be 1-(2,4-dihydroxy-6-methoxy-3-methylphenyl)-2-hydroxyethanone, and one monoglucuronide, isolated and determined by hydrolysis with ␤-glucuronidase, mass spectrometry, and 1 H NMR to be 2-hydroxy-6-methoxy-3-methyl-acetophenone-4-O-␤-glucuronide, were observed in human liver microsomal incubates in the presence of NADPH or UDP-glucuronic acid (UDPGA), respectively. However, the mixed incubation of ECB with human liver microsomes in the presence of both NADPH and UDPGA showed the monoglucuronide to be the most major metabolite, indicating that glucuronidation was probably the major clearance pathway of ECB in humans. No glucuronide and only trace monohydroxylation metabolite were observed in HepG2 cells. The cytochrome P450 and UDPglucuronosyltransferase (UGT) isoenzymes were identified by using selective chemical inhibition and recombinant human enzymes. The results indicated that CYP3A4 was probably involved in ECB oxidative metabolism and UGT1A6 and UGT1A9 were important catalytic enzymes in ECB glucuronidation. The results from enzymatic kinetic analysis showed the oxidative metabolism in human liver microsomes; the glucuronidation in human liver microsomes and recombinant UGT1A6 exhibited a typical Michaelis-Menten pattern, but the glucuronidation in UGT1A9 exhibited a substrate inhibition pattern. UGT1A6 had the highest affinity compared with human liver microsomes and UGT1A9, indicating its important role in ECB glucuronidation.
Introduction
Tuberculosis is a leading cause of death from infectious diseases worldwide and drug-resistant (XDR) tuberculosis (TB) continues to spread in many parts of the world. Developing new antituberculosis agents, especially XDR-TB inhibitors, is a long-term and urgent task (Dye, 2006; Raviglione and Smith, 2007) .
Euphorbia ebracteolata and Euphorbia fischeriana are very famous traditional herbal medicines and have been extensively used as a tuberculocide in the Asian countries (Jiangsu College of New Medicine, 1986; Zhang et al., 1987 Zhang et al., , 2010 ; Modern pharmacological investigations also indicated that the extracts of these plants possess significant antituberculosis activities (Zhao et al., 2000 (Zhao et al., , 2007 . Ebracteolata compound B (ECB, 2, 4-dihydroxy-6-methoxy-3-methyl-acetophenone), the main active component of E. ebracteolata and E. fischeriana (Su et al., 2003 (Su et al., , 2006 was reported to possess significant antituberculosis activities (Zhang et al., 1987; Zhang and Ding, 1992; Song et al., 2007; Zhao et al., 2007) . The complete inhibitory concentrations for tuberculosis bacillus and XDR-TB bacillus were reported to be 0.1 and 0.8 mg/ml, respectively (Zhao et al., 2007) . The compound 2,4-dihydroxy-6-methoxyl-methylene-3-methylacetophenone, the structure of which is very similar to that of ECB, was reported to exhibit obvious selective activity against human HeLa-60 tumor cells with an IC 50 value of 0.95 ϫ 10 Ϫ1 g/ml (Zhang et al., 2010) . However, ECB metabolism is still unclear.
Drug metabolism may lead to detoxification and/or activation reactions, and a drug metabolism study can assist in identifying active compounds and explaining their mechanisms of action. Liver is mainly responsible for the biotransformation of the majority of xenobiotics. Human liver microsomes, expressed cytochrome P450s (P450s), and UDP-glucuronosyltransferases (UGTs) are the most common models used in predicting routes and rate of xenobiotic metabolism or evaluating the contributions of individual enzymic activities (Qian et al., 2004; Chen et al., 2006 Chen et al., , 2008 Zheng et al., 2006; Yu et al., 2007; Liu and Zeng, 2009; Wang and Zeng, 2009) . HepG2 is one of the best-characterized human hepatoma cell line and has been confirmed to be a suitable model to study biotransformation and roles of most common P450, glutathione transferase, and UGT enzymes (Birringer et al., 2001; Brandon et al., 2006; Westerink and Schoonen, 2007a,b) . In addition, compared with primary human hepatocytes, HepG2 is a relatively easy-to-handle tool. Accordingly, HepG2 is frequently used for human biotransformation studies (Renner et al., 2002; Yamamoto et al., 2002; Asai et al., 2004; Lançon et al., 2007) .
In this study, we investigated oxidative metabolism and glucuronidation metabolism of ECB by human liver microsomes through high-performance liquid chromatography (HPLC) and UPLC-MS. Likewise, ECB metabolism in HepG2 cells was analyzed. Recombinant human CYP3A4 and recombinant human UGTs were used to identify the isoenzymes involved in ECB metabolism in combination with enzymatic kinetic analysis and selective chemical inhibition.
Materials and Methods
Ebracteolata Compound B. ECB ( Fig. 1 ) was isolated and purified from the extract of E. fischeriana by organic solvent extraction, silica gel column chromatography, medium pressure column (C8) chromatography, and semipreparative HPLC in our laboratory. The purity was determined to be Ͼ98% based on HPLC. The structures were identified by UPLC-ESI-MS and 1 H NMR as the described in the literature (Liu et al., 2001; Su et al., 2006) .
Chemicals. The extract of E. fischeriana (1.0 kg) was purchased from Nanjing Qingze Medical Technological Development Co. Ltd. (Nanjing, China). The human hepatoma HepG2 cells (passage 26) were obtained from the Shanghai Cellular Research Institute (Shanghai, China). DNA molecular marker and T4 ligase, were obtained from MBI Fermentas (Amherst, NY). Agarose LE was supplied by Roche Diagnostics (Mannheim, Germany). PCR primers were obtained from Sangon (Shanghai, China). Dulbecco's modified Eagle's medium and nonessential amino acids, Bac-to-Bac expression system, Grace's medium, fetal bovine serum, Cellfectin reagent, and all other supplement reagents were from Invitrogen (Carlsbad, CA). Trisodium isocitric acid, isocitric dehydrogenase, ␤-NADP and its reduced form (␤-NADPH), 4-methylpyrazole, sulfamethoxazole, quinidine sulfate, ketoconazole, ␣-naphthoflavone, cimetidine, UDP-glucuronic acid (UDPGA), and ␤-glucuronidase were purchased from Sigma-Aldrich (St. Louis, MO). Fluvoxamine were received from the Department of Medicinal Chemistry (Zhejiang University, Hangzhou, China). All other chemicals were purchased from standard commercial sources and were of the highest quality available.
Human liver samples were obtained from the Sir Run Run Shaw Hospital (Zhejiang, China). Informed consent was obtained from each patient before study entry. The present study was approved by an ethics committee of our university. All human livers used in the study were obtained from normal portions of removed tissue and stored at Ϫ80°C before used.
Preparation of Human Liver Microsomes. All human liver microsomes were prepared as described previously (Gibson and Skett, 1994) . Protein concentration was determined by the method of Lowry et al. (1951) , using bovine serum albumin as the standard.
ECB Metabolism in HepG2 Cells. HepG2 cell culture. HepG2 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal calf serum and 1% nonessential amino acids, pH 7.4. Cell viability was assessed by a trypan blue exclusion test. Cultures were maintained in a humidified atmosphere with 5% CO 2 at 37°C. The medium was refreshed every 2 or 3 days, and cells were trypsinized by 0.25% trypsin-0.02% EDTA when the cells reached to 80 to 90% confluence. 
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Cytotoxicity studies. To use a proper concentration range for ECB metabolism study in HepG2 cells, the cytotoxic effects of ECB on HepG2 cells were determined by the 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. In brief, HepG2 cells were exposed to ECB with different concentrations or controls. After exposed, cells were washed once with 37°C phosphate-buffered saline (PBS), and then 0.1 ml of serum-free medium containing 0.05% MTT was added to each well. After incubation for 4 h, the culture medium was removed, and 0.1 ml of DMSO was added to each well to solubilize the formazan formed. The plates were shaken gently for 10 min, and the absorbance was measured at 570 nm. The absorbance of exposed cells was compared with the absorbance of the control cells, which were exposed only to the vehicle and were considered as the 100% viability value.
Assay of ECB metabolism in HepG2 cells. The well-grown cells of passage 28 were harvested and seeded into six-well plates at a density of 2 ϫ 10 6 cells/ml. After cells attached, the medium was replaced with serum-free culture medium, and the cells were exposed to ECB with 50 M for 24 h. Then the cells were sonicated and homogenized. ECB metabolism in the cell was analyzed by using UPLC-MS.
Preparation of Recombinant Human CYP3A4. Recombinant human CYP3A4 homogenates were prepared as described in our laboratory (Wang and Zeng, 2009 ). In brief, Sf9 cells were coinfected by recombinant baculovirus of CYP3A4, NADPH-cytochrome P450 oxidoreductase, and cytochrome b 5 . Cells were harvested 96 h after the first infection. The cells were sonicated in lysis solution (pH 7.4) on ice, 6-s bursts six times, with at least a 15-s interval. The protein concentration of the homogenate was measured by the method of Lowry et al. (1951) using bovine serum albumin as the standard.
Determination of Enzyme Activity of Recombinant Human CYP3A4. The activities of recombinant human CYP3A4 and human liver microsomes served as positive controls and were determined by using midazolam as a classic substrate (Miyazaki et al., 2008) . The incubation medium contained 0.1 M Tris-HCl (pH 7.4), 15 mM MgCl 2 , 12 mM dl-isocitrate trisodium, 0.08 unit of isocitrate dehydrogenase, 1.5 mg/ml recombinant human CYP3A4 homogenate protein or 0.5 mg/ml human liver microsomes, and 15.7 M midazolam (midazolam was dissolved in DMSO and the final concentration of organic solvent did not exceed 1%). The final incubation volume was 0.1 ml. The mixture was preincubated at 37°C for 3 min, and then 2 l of NADP/NADPH solution was added to the reaction mixture and incubation was performed at 37°C for 20 min. The reaction was stopped by addition of 300 l of ice-cold methanol. After centrifugation, the supernatant was analyzed by HPLC.
Preparation of Recombinant Human UGTs. Recombinant human UGT (UGT1A3, UGT1A4, UGT1A6, UGT1A9, and UGT2B7) homogenates were prepared as described in our laboratory (Qian et al., 2004; Chen et al., 2006 Chen et al., , 2008 Zheng et al., 2006; Yu et al., 2007) . In brief, recombinant pFastBac1-UGTs were transformed into DH10Bac cells for transposition into bacmids. After two cycles of blue/white selections, a white colony was selected to culture in LB medium. Recombinant bacmid-UGTs were isolated and analyzed by PCR using the M13 forward and M13 reverse primers, flanking the mini-attTn7 site within the lacZ␣ complementation region on bacmid. Hosts for expression, Sf9 cells, were usually grown at 27°C in Grace's medium containing 10% fetal bovine serum, transfected at 50 to 60% of confluence using Cellfectin reagent in serum-free medium. After 72 h, the first passage of baculovirus was harvested from supernatant and titrated by fluorescence quantitative-PCR. Infection conditions were optimized for subsequent amplification or expression. Cells were harvested by centrifugation at 72 h postinfection and rinsed twice with PBS, pH 7.4. Cells suspensions in PBS were sonicated six times with 7 s of burst, allowing at least 1 min on ice between bursts, and were stored at Ϫ80°C for further analysis. The relative expression level of each UGT was ascertained by Western blot using the mouse anti-His antibody. A peroxidase-conjugated goat anti-mouse antibody was used as the secondary antibody. The protein concentration of the cell homogenate was determined by using the method of Lowry et al. (1951) . Cell homogenate was stored frozen at approximately Ϫ80°C until use. Transfection with an untransposed bacmid was performed as a negative control. The activities of UGTs (UGT1A3, UGT1A6, UGT1A9, and UGT2B7) were determined by using 7-hydroxy-4-trifluoromethylcoumarin as a substrate, and the activity of UGT1A4 was determined by using trifluoperazine as a substrate as in our previous method (Yu et al., 2007) .
HPLC Analysis. HPLC analysis was performed on a high-performance liquid chromatographic system (Agilent 1100; Agilent Technologies, Santa Clara, CA) equipped with a G1322A degasser, a G1310A quaternary pump, a G1313A autosampler, and a G1315B diode array detector. The chromatographic data were processed using an Agilent ChemStation (Rev. B.03.01). HPLC separation was achieved on a reverse-phase Diamonsil C18 (250 ϫ 4.6 mm i.d., 5 m) column equipped with a C18 guard column (15 ϫ 4.6 mm i.d., 5 m) maintained at room temperature.
The mobile phase for analysis of ECB and its metabolites consisted of a mixture of solvent A (0.1% formic acid solution) and solvent C (methanol). The gradient started at 70% A and 30% C, followed by a linear increase of solvent C to 90% from 0 to 17 min and hold for 3 min. The initial conditions were returned to in a linear mode from 20 to 25 min, and then the column was equilibrated for 3 min. The flow rate was 1.0 ml/min. The injection volume was 50 l. The spectra were obtained with the diode array detector from 200 to 400 nm. The quantity of ECB and its metabolites was measured at 280 nm by peak area comparison to the internal standard (acetophenone) using a standard curve of ECB or its metabolites spiked in the assay medium.
The mobile phase for analysis of midazolam and its metabolites was methanol-10 mM ammonium acetate (6:4) at a flow rate of 1.0 ml/min. The detection wavelength was 220 nm. The injection volume was 20 l.
UPLC-MS Analysis. All UPLC was performed using a Waters Acquity UPLC system (Waters, Milford, MA). All UPLC separations were achieved using an Acquity UPLC BEH C18 column (50 ϫ 2.1 mm i.d., 1.7 m; Waters) maintained at room temperature, and the sample injection volume was 10 l. The mobile phase consisted of a mixture of solvent A (0.1% formic acid solution) and solvent B (acetonitrile) and was delivered at a constant rate of 0.25 ml/min. For the oxidative metabolite assay, the gradient started at 85% A and 15% B for 1 min, followed by a linear increase of solvent B to 80% from 1 to 6 min, and initial conditions were returned to in a linear mode from 6 to 6.1 min; the column was then equilibrated from 6.1 to 7 min. For the glucuronide analysis, the gradient started at 95% A and 5% B for 1 min, followed by a linear increase of solvent B to 80% from 1 to 8 min, and initial conditions were returned to in a linear mode from 8 to 8.5 min; the column was then equilibrated from 8.5 to 10 min.
All mass spectrometric experiments were performed on a Waters Acquity triple quadrupole mass spectrometer equipped with an ESI interface. Negative ion ESI mode was used to analyze ECB together with its metabolites. Full-scan MS (m/z 100 -500) experiments and selected ion recording (SIR) were performed. The parameters were tuned as follows: capillary, 1.60 kV; cone, Ϫ33 V; extractor, Ϫ3 V; source temperature, 120°C; and desolvation temperature, 250°C. Nitrogen (99.9% purity) was used as the desolvation and cone gas at flow rates of 500 and 0.1 l/h, respectively. The product ion mass spectra were acquired by scanning MS/MS from m/z 40 to 500. The selected precursor ions underwent collision-induced dissociation in the central hexapole collision cell. The collision energies ranged from 40 to 45 eV. Argon (99.9999% purity) was used as the collision gas at a flow rate from 0.10 to 0.12 l/h. The other parameters were set as those in the full-scan and SIR mode. Data collected was processed using MassLynx version 4.1 software.
Oxidative Metabolism by Human Liver Microsomes or Recombinant Human CYP3A4. The sample was incubated in 100 l of buffer containing 0.1 M Tris-HCl (pH 7.4), 15 mM MgCl 2 , 12 mM dl-isocitrate trisodium, 0.08 unit of isocitrate dehydrogenase, human liver microsomes (1.0 mg/ml) or recombinant human CYP3A4 homogenate protein (1.5 mg/ml) and approximately 200 M ECB (ECB was dissolved in DMSO and the final concentration of organic solvent did not exceed 1%), and the mixture was preincubated at 37°C for 3 min. Then 2 l of NADP/NADPH solution (0.026 M NADP and 0.012 M NADPH in 0.12 M NaHCO 3 ) was added to each reaction mixture. After incubation at 37°C for different periods of time in a shaking water bath, the reaction was terminated by addition of 300 l of ice-cold methanol. The contents were vortex-mixed for 30 s and centrifuged at 13,000 rpm for 10 min. The supernatant was analyzed by HPLC or UPLC-MS. Control incubations with inactive microsomes (microsomes were heated for 30 min at 95°C) or without cofactors were performed in parallel.
METABOLISM OF EBRACTEOLATA COMPOUND B
P450 inhibitors were added to the incubation mixture, which contained human liver microsomes to assess the enzymes involved. Inhibitors were dissolved in DMSO, and control incubations were spiked with the same amount of DMSO (less than 1%, v/v). The same incubation procedure as described above was followed, except that the inhibitors were added to the incubation medium before the reaction was started. The metabolite formation rates in the presence of inhibitors were compared with those of the corresponding controls and the percentage of inhibition was calculated.
Glucuronidation Metabolism in Human Liver Microsomes or Recombinant Human UGTs. Glucuronidation was investigated by incubating in 100 l of 0.1 M K 2 HPO 4 buffer (adjusted to pH 7.5 with H 3 PO 4 ) containing human liver microsomal protein (1.0 mg/ml) or recombinant human UGTs homogenate protein (1.5 mg/ml), 112.5 g/ml Triton X-100, 10 mM MgCl 2 , 50 mM Tris-HCl (pH 7.4), and approximately 200 M ECB (ECB was dissolved in DMSO, and the final concentration of organic solvent did not exceed 1%), and the mixture was preincubated at 37°C for 3 min. Then 4 l of UDPGA solution (77.4 mM UDPGA in 0.1 M K 2 HPO 4 buffer, adjusted to pH 7.5 with H 3 PO 4 ) was added to each reaction mixture. After incubation at 37°C for different periods of time in a shaking water bath, the reaction was terminated by addition of 300 l of ice-cold methanol. After centrifugation, the supernatant was analyzed by HPLC-UV and UPLC-MS. Control incubations with inactive microsomes or without cofactors were performed in parallel.
The ␤-glucuronidase assay was performed as follows. An aliquot of 200 l of glucuronidation incubate was heated for 30 min at 95°C and then divided into two equal parts. One part was treated with 10 l of KH 2 PO 4 buffer (0.1 M, pH 5.0) containing 1000 units of ␤-glucuronidase at 37°C for 2 h; the other part without ␤-glucuronidase was treated in parallel, and, after treatment, 300 l of ice-cold methanol was added to both parts. After centrifugation, the supernatant was analyzed by HPLC.
Isolation and 1 H NMR analysis of the ECB glucuronide was performed as follows. Approximately 500 ml of human liver microsomal incubates was subjected to macroporous absorption resin D101 eluted with H 2 O-ethanol in a stepwise manner. The 40% ethanol elution was evaporated to dryness in a rotary evaporator at 40°C under vacuum. The residue was redissolved in methanol and further purified by semipreparative HPLC with a mobile phase consisting of 52% methanol and 48% water-formic acid (100:0.1, v/v). The purity was determined to be Ͼ98% based on HPLC. The structure was identified by 1 H NMR and compared with the parent drug ECB and other related drugs in the literature (Zhang and Ding, 1992; Liu et al., 2001; Zhang et al., 2010) .
The mixed incubation of oxidative and glucuronidation metabolism was investigated in 100 l of buffer containing 0.1 M Tris-HCl (pH 7.4), 15 mM MgCl 2 , 12 mM dl-isocitrate trisodium, 0.08 unit of isocitrate dehydrogenase, 112.5 g/ml Triton X-100, 1 mg/ml human liver microsomes, and approximately 200 M ECB (ECB was dissolved in DMSO and the final concentration of organic solvent did not exceed 1%). The mixture was preincubated at 37°C for 3 min. Then 2 l of NADP/NADPH solution and 4 l of UDPGA solution were added to the reaction mixture, and incubation was performed at 37°C for 30 min. The reaction was stopped by addition of 300 l of ice-cold methanol. After centrifugation, the supernatant was analyzed by HPLC.
The glucuronidation activity of ECB at a concentration of 200 M was measured in pooled human liver microsomes in the presence of known UGT inhibitors. The chemical inhibitors included quercetin for UGT1A3 (Zheng et al., 2006; Yu et al., 2007) , trifluoperazine for UGT1A4 (Kaku et al., 2004) , phenylbutazone for UGT1A6 (Liu et al., 2008) , propofol for UGT1A9 (Williams et al., 2004; Tachibana et al., 2005) , and diclofenac for UGT2B7 (King et al., 2001 ). All inhibitors were dissolved in DMSO and were added to the incubation mixtures at final concentrations ranging from 0 to 800 M. Control incubations containing all components of the incubation mixtures, including 1% (v/v) DMSO, but no inhibitors, were performed in parallel. The glucuronidation activities were calculated as a percentage of control activity.
Determination of Kinetic Constants. After checking for the linearity of metabolite formation with increasing microsomal protein concentration (0.2-1.2 mg/ml) or recombinant human UGTs homogenate protein concentration (0.5-2.0 mg/ml) and incubation time (5-60 min), the kinetic constants of oxidative metabolism and glucuronidation metabolism were determined with the substrate (ECB) at a series of concentrations. K m and V max values were estimated on the basis of the oxidative metabolite or monoglucuronide formation by substitution into the Michaelis-Menten or substrate inhibition equation using a nonlinear regression program in Prism software (version 5.0; GraphPad Software Inc., San Diego, CA). Intrinsic clearance was calculated by the ratio of V max /K m .
Statistical Analysis. The results are expressed as the mean Ϯ S.D. All calculations were performed using Microsoft Excel 2003 or Prism version 5.0 software. Statistical differences were tested by unpaired t test using Prism version 5.0 software.
Results
Oxidative Metabolism. Identification of metabolite formed by human liver microsomes. When ECB was incubated with human liver microsomes in the presence of NADPH, one metabolite was clearly detected by HPLC. The formation of the metabolite was dependent on the presence of NADPH and appeared to be linear with respect to incubation time (up to 40 min) and microsomal protein concentration (up to 1.2 mg/ml) (data not shown). Moreover, the metabolite was not clearly observed in incubates with heat-inactivated microsomes or in the absence of NADPH.
UPLC-MS analysis of the incubation mixture was performed. ECB was eluted at 4.3 min; the metabolite was eluted at 2.7 min. In the negative ESI-MS spectrum, ECB and the metabolite were all observed as deprotonated molecular ions [M Ϫ H] Ϫ at m/z 195 and 211, respectively (Fig. 1, A and B) . The short retention time of the metabolite indicated that this metabolite was more polar than ECB. Moreover, the metabolite was 16 Da higher than ECB. These suggested that the metabolite was a monohydroxylation metabolite of ECB. In the negative ESI-MS/MS spectrum, the precursor ion at m/z 211 produced relatively stable fragment ions at m/z 153 and 137 (Fig.  1C) , which was consistent with hydroxylation on the C8 position. The formation of the ion at m/z 153 might result from the heterolytic cleavage of the C7-C1 bond. The ion at m/z 153 might further, via a loss of CH 4 , form the ion at m/z 137. A scheme proposed for the formation of the ions at m/z 153 and 137 is illustrated in Fig. 1D . The molecular formula of the ECB monohydroxylation metabolite was C 10 H 12 O 5 , and its structure was elucidated as 1-(2,4-dihydroxy-6-methoxy-3-methylphenyl)-2-hydroxyethanone.
Kinetics of ECB oxidative metabolism by human liver microsomes. Kinetic analysis of ECB oxidative metabolism was performed in human liver microsomes. The ECB oxidative metabolite was isolated, and its purity was determined to be Ͼ98% based on HPLC. The quantity was measured by the peak area comparison of the ECB oxidative metabolite to the internal standard (acetophenone) using a standard curve of the ECB oxidative metabolite spiked in the assay medium. This calculation was also applied to metabolite formation in the inhibition analysis of ECB oxidative metabolism by human liver microsomes. The oxidative metabolite formation followed typical Michaelis-Menten kinetics. The estimated K m and V max values were 378.2 Ϯ 95.6 M and 12.1 Ϯ 1.7 nmol/min ⅐ mg protein, respectively.
Inhibition analysis of ECB oxidative metabolism by human liver microsomes. When ECB was incubated with human liver microsomes in the presence of the specific P450 inhibitors ␣-naphthoflavone (CYP1A2), quinidine sulfate (CYP2D6), 4-methylpyrazole (CYP2E1), and cimetidine (CYP2C19), the percentages of inhibitive effect were all less than 20%. The other three inhibitors, ketoconazole (CYP3A), fluvoxamine (CYP1A2 and CYP3A4), and sulfamethoxazole (CYP2C9) had more or less inhibitive effects with percentages from 33 to 65%, and both ketoconazole and fluvoxamine had notable inhibitive effects (detailed results are seen in Fig. 2) . The results indicated that the CYP3A isoform was probably involved in ECB oxidative metabolism (Gradolatto et al., 2004; Xia et al., 2007; Liu and Zeng, 2009 ).
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ECB metabolism by recombinant human CYP3A4. The activities of recombinant human CYP3A4 (wild-type) and human liver microsomes using midazolam as a classic substrate were approximately 394.7 Ϯ 32.4 and 8820.3 Ϯ 658.1 pmol/[min ⅐ mg (protein)], respectively. These results demonstrated that the recombinant human CYP3A4 and human liver microsomes were active. When ECB was incubated with these recombinant human CYP3A4 homogenates in the presence of NADPH, one metabolite was clearly detected, and the metabolite was assigned as the same structure based on retention time and MS/MS spectral properties as that formed by human liver microsomes. The activities, based on substrate depletion, of these recombinant human CYP3A4 homogenates and human liver microsomes toward ECB were approximately 573.0 Ϯ 41.2 and 9612.5 Ϯ 754.1 pmol/[min ⅐ mg (protein)], respectively. Glucuronidation Assay. ECB glucuronidation by human liver microsomes. When ECB was incubated with human liver microsomes in the presence of UDPGA, one metabolite was clearly detected by HPLC. The formation of the metabolite was dependent on the presence of UDPGA and appeared to be linear with respect to incubation time (up to 30 min) and microsomal protein concentration (up to 1.2 mg/ml). Furthermore, the metabolite was not detected in incubates with heat-inactivated microsomes or in the absence of the UDPGA (data not shown).
UPLC-MS analysis of the incubation mixture was performed. The metabolite and the substrate were all observed as deprotonated molecular ions [M Ϫ H] Ϫ . The peak at retention time of 6.4 min appearing at m/z 195 was the substrate ECB; the peak at retention time of 4.6 min appearing at m/z 371 corresponded to monoglucuronidation of ECB (Fig. 3, A and B) . In the negative ESI-MS/MS spectrum, the
Ϫ ion at m/z 371 eliminated 176 mass units (glucuronic acid) to give an ion at m/z 195, further indicating that the metabolite was ECB monoglucuronide (Fig. 3C) .
Hydrolysis with ␤-glucuronidase. The ECB monoglucuronide was easily hydrolyzed by ␤-glucuronidase and converted to parent ECB. No change was observed for the ECB glucuronide over the 24 h of incubation without ␤-glucuronidase and placement for 24 h at room temperature. Therefore, all detected ECB in the presence of the ␤-glucuronidase could be attributed to enzymatic hydrolysis. The detected ECB was quantified by the method described under HPLC Analysis. The glucuronide content could be calculated from the detected ECB content. This procedure was applied to the quantification of the ECB glucuronide formed in the microsomal or recombinant human UGT incubation mixture for determination of kinetic constants.
1 H NMR analysis of the ECB monoglucuronide. The ECB glucuronide (approximately 4.6 mg) was isolated from human liver microsomal incubates and was determined by 1 H NMR analysis. In the 1 H NMR (DMSO-d 6 ) spectrum (Fig. 4) , the signal of 4-OH disappeared and the additional anomeric proton signal [␦ 5.27, 1H, d , J ϭ 7.5 Hz, H-1] indicated the presence of glucuronide. Furthermore, the spectrum showed signals similar to those of the ECB skeleton (Liu et al., 2001 ) except for the downfield shift of H-5 by 0.26 ppm. On the other hand, the spectrum also showed signals that were very similar to 2-hydroxy-6-methoxy-3-methyl-acetophenone-4-␤-glucuronide and 2-hydroxy-6-methoxyl-methylene-3-methyl-acetophenone-4-O-␤-Dglucopyranoside (Zhang and Ding, 1992; Zhang et al., 2010) . Accordingly, the linkage site of the glucuronic acid should be on the position 4-OH. The full assignments of proton signals are summarized in Table 1 . 
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The molecular formula of the ECB monoglucuronide is C 16 H 20 O 10 , and its structure was elucidated as 2-hydroxy-6-methoxy-3-methylacetophenone-4-O-␤-glucuronide (Fig. 4) .
Kinetics of ECB glucuronidation by human liver microsomes. Kinetic analysis of ECB glucuronidation was performed in human liver microsomes. ECB was incubated with human liver microsomes in the presence of UDPGA for 20 min. The ECB glucuronidation by human liver microsomes displayed typical Michaelis-Menten kinetics. The kinetic parameters based on the metabolite formation are shown in Table 2 .
Analysis of mixed incubates of ECB with human liver microsomes in the presence of both NADPH and UDPGA. The mixed incubation of ECB with human liver microsomes in the presence of both NADPH and UDPGA was investigated. Two metabolites were detected. One was assigned as the monohydroxylation metabolite, and the other was assigned as the monoglucuronide based on the HPLC retention time. However, compared with the monohydroxylation metabolite, the monoglucuronide was the major metabolite. After a 30-min incubation, more than 80% was metabolized into ECB monoglucuronide. The results indicated that glucuronidation was the major clearance pathway in humans.
ECB glucuronidation by recombinant UGT isoforms. The activities of five recombinant UGT isoforms expressed in baculovirus-infected insect cells and human liver microsomes serving as positive controls by using 7-hydroxy-4-trifluoromethylcoumarin or trifluoperazine (for UGT1A4) as a classic substrate were measured. The results showed 
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that all recombinant UGTs and human liver microsomes were active, and no activity was found in the insect control. All recombinant UGTs were used to determine their ECB glucuronosyltransferase activities (Fig. 5C ). Only UGT1A6 and UGT1A9 exhibited remarkably high ECB glucuronidation activities. The other isoforms (UGT1A3, UGT1A4, and UGT2B7) had very low ECB glucuronidation activities or no activities. The results from ␤-glucuronidase hydrolysis indicated that the metabolite was glucuronide, and the metabolite was assigned as the same structure as that formed by human liver microsomes based on chromatographic retention time and MS/MS spectral properties.
Kinetic analysis of ECB glucuronidation in recombinant UGT1A6 and UGT1A9 was performed. ECB was incubated with UGT1A6 or UGT1A9 in the presence of UDPGA for 20 min. ECB glucuronidation by recombinant UGT1A6 displayed typical Michaelis-Menten kinetics, similar to that by human liver microsomes, whereas ECB glucuronidation by recombinant UGT1A9 exhibited substrate inhibition kinetics. The kinetic parameters are shown in Table 2 . The kinetic parameters were calculated with GraphPad Prism software. Each value represents the mean Ϯ S.D. of three independent experiments.
Inhibition analysis of ECB glucuronidation by human liver microsomes. The inhibitory effects of quercetin (UGT1A3), trifluoperazine (UGT1A4), phenylbutazone (UGT1A6), propofol (UGT1A9), and diclofenac (UGT2B7) on the ECB glucuronosyltransferase activities in human liver microsomes were investigated. Likewise, the inhibitory effect of phenylbutazone on the ECB glucuronosyltransferase activities in recombinant human UGT1A6 was investigated. As shown in Fig. 5B , the ECB glucuronosyltransferase activity in human liver microsomes was prominently inhibited by phenylbutazone and propofol. Quercetin, trifluoperazine, and diclofenac showed very weak inhibitory effects. In addition, phenylbutazone had a notable inhibitive effect on ECB glucuronosyltransferase activity in recombinant human UGT1A6 (Fig. 5A) .
ECB Metabolism by HepG2 cells. HepG2 cell cytotoxicity. The exposure of HepG2 cells to ECB (final concentrations 0, 20, 40, 60, 80, 100, 150, 200, 300 , and 400 M) caused concentration-dependent cell death indicated with the MTT assay. The IC 50 for 24 h of exposure to ECB was 193.6 M. At less than 80 M, no obvious toxic effect was observed. Each concentration with five replicates was tested three times. The final concentration of DMSO in the test or control medium was less than 1%.
ECB metabolism assay by HepG2 cells. When the cell homogenate was analyzed by UPLC-MS, no glucuronide was detected and only trace monohydroxylation metabolite of ECB was observed. The metabolite was assigned as the same structure as that formed in human liver microsomes.
Discussion
ECB is one major component of E. ebracteolata and E. fischeriana used to treat tuberculosis. However, to date, ECB metabolism is unclear, and an understanding of ECB metabolism in humans is needed. Hence, we studied ECB metabolism in vitro by using human liver microsomes, HepG2 cells, and recombinant human enzymes.
ECB was incubated with human liver microsomes. In the presence of NADPH, one monohydroxylation metabolite was clearly detected and identified as 1-(2,4-dihydroxy-6-methoxy-3-methylphenyl)-2-hydroxyethanone on the basis of UPLC-ESI-MS/MS analysis. In the presence of UDPGA, one monoglucuronide was obviously detected and identified as 2-hydroxy-6-methoxy-3-methyl-acetophenone-4-O-␤-glucuronide on the basis of UPLC-ESI-MS/MS, 1 H NMR analysis, and hydrolysis with ␤-glucuronidase. Although the biological function of the ECB-4-O-␤-glucuronide was unknown, ECB-4-O-␤-glucoside was reported to exhibit significant activity against tuberculosis bacillus (Zhang and Ding, 1992) , and 2-hydroxy-6-methoxyl-methylene-3-methyl-acetophenone-4-O-␤-D-glucopyranoside recently isolated from E. ebracteolata was reported to display notably selective activity against A-549 and MCF-7 tumor cells with IC 50 values of 8.79 ϫ 10 Ϫ1 and 3.46 ϫ 10 Ϫ1 g/ml (Zhang et al., 2010) . The biological function of the ECB-4-O-␤-glucuronide deserved further study.
The mixed incubation of ECB with human liver microsomes in the presence of both NADPH and UDPGA was investigated. The monohydroxylation metabolite and the monoglucuronide of ECB were all observed in the human liver microsomal incubates. However, compared with the monohydroxylation metabolite, the monoglucuronide was the major metabolite, indicating that glucuronidation was the major clearance pathway of ECB in humans.
Two approaches were used to identify the P450 isoenzymes involved in ECB oxidative metabolism by human liver microsomes. These were based on selective chemical inhibitors and recombinant human CYP3A4. Of all inhibitors tested, notable inhibition was observed only with ketoconazole (CYP3A) and fluvoxamine (CYP1A2 and CYP3A). In addition, the results from recombinant human CYP3A4 metabolism indicated that CYP3A4 was probably involved. In a word, the results suggested the involvement of CYP3A4 in ECB oxidation metabolism by human liver microsomes.
In the similar manner, UGT isoenzymes involved in ECB glucuronidation were identified. First, selective chemical inhibition experiments were performed. Of five inhibitors tested, notable inhibition was observed with phenylbutazone (UGT1A6) and propofol (UGT1A9). Then, a panel of recombinant human UGT enzymes (UGT1A3, UGT1A4, UGT1A6, UGT1A9, and UGT2B7) was screened. UGT1A6 When ECB was incubated with HepG2 cells, only trace hydroxylation metabolite was detected and no glucuronide was detected, indicating poor ECB metabolism activities due to low expression levels of cytochrome P450 enzymes and UGT1A1 and UGT1A6 in HepG2 cells (Westerink and Schoonen, 2007a,b) . The results also suggested that CYP3A and UGT1A6 are important isoenzymes, probably involved in ECB metabolism. 
